TSE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis C$5.23 0.00 (0.00%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider Trades About Medexus Pharmaceuticals Stock (TSE:MDP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MDP alerts:Sign Up Key Stats Today's RangeC$5.16▼C$5.3050-Day RangeC$4.04▼C$5.4552-Week RangeC$2.51▼C$5.50Volume81,099 shsAverage Volume48,781 shsMarket CapitalizationC$164.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology and allergy. Read More Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDP Stock News HeadlinesMedexus Pharmaceuticals (TSE:MDP) Shares Down 0.2% - Should You Sell?September 2 at 1:40 AM | americanbankingnews.comMedexus Pharmaceuticals Inc.: Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to DateAugust 10, 2026 | finanznachrichten.deThis Overlooked Fund Turns AI Stocks Into Weekly IncomeA small fund pays investors weekly income from AI stocks that don't pay dividends on their own. Chief Income Strategist Tim Plaehn explains how the fund converts AI exposure into a regular Thursday payout in a free video presentation.September 2 at 1:00 AM | Investors Alley (Ad)Medexus Pharmaceuticals Inc.: Medexus Schedules First Fiscal Quarter 2027 Conference CallJuly 30, 2026 | finanznachrichten.deMedexus Pharmaceuticals Inc.: Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for ...June 26, 2026 | finanznachrichten.deShareholders in Medexus Pharmaceuticals (TSE:MDP) are in the red if they invested five years agoNovember 10, 2025 | finance.yahoo.comEarnings To Watch: Medexus Pharmaceuticals Inc (TSX:MDP) Reports Q1 2026 ResultAugust 14, 2025 | finance.yahoo.comMedexus Pharmaceuticals Inc. (MDP) Stock Price Today - WSJJuly 15, 2025 | wsj.comSee More Headlines MDP Stock Analysis - Frequently Asked Questions How have MDP shares performed this year? Medexus Pharmaceuticals' stock was trading at C$2.91 at the beginning of 2026. Since then, MDP stock has increased by 79.7% and is now trading at C$5.23. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS). Company Calendar Today9/02/2026AGM 20269/24/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolTSE:MDP CIKN/A Webwww.medexus.com Phone877-633-3987FaxN/AEmployees98Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.07) Trailing P/E RatioN/A Forward P/E Ratio32.02 P/E GrowthN/ANet IncomeC$3.26 million Net Margins-2.32% Pretax MarginN/A Return on Equity-4.72% Return on Assets4.89% Debt Debt-to-Equity Ratio54.62 Current Ratio1.30 Quick RatioN/A Sales & Book Value Annual SalesC$103.30 million Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.51 per share Price / Book3.47Miscellaneous Outstanding Shares31,426,000Free FloatN/AMarket CapC$164.36 million OptionableNot Optionable Beta0.20 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (TSE:MDP) was last updated on 9/2/2026 by MarketBeat.com Staff. From Our PartnersPass by August 7… or wait until 2027?Right now, crypto investors are watching Washington closely. With lawmakers returning from the August recess, ...Crypto 101 Media | SponsoredGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"The federal government is throwing its full support behind a new class of AI technology, in what's being calle...Stansberry Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | Sponsored200 companies were warned. 40% found the intruder.A cybersecurity firm warned roughly 200 companies they might have a fake employee on payroll. After investigat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
